CN1199641C - 一种用于治疗高血压的复方厄贝沙坦胶囊 - Google Patents
一种用于治疗高血压的复方厄贝沙坦胶囊 Download PDFInfo
- Publication number
- CN1199641C CN1199641C CN 02146334 CN02146334A CN1199641C CN 1199641 C CN1199641 C CN 1199641C CN 02146334 CN02146334 CN 02146334 CN 02146334 A CN02146334 A CN 02146334A CN 1199641 C CN1199641 C CN 1199641C
- Authority
- CN
- China
- Prior art keywords
- irbesartan
- cross
- blood pressure
- adjuvant
- high blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 title claims abstract description 14
- 239000002947 C09CA04 - Irbesartan Substances 0.000 title claims abstract description 13
- 239000002775 capsule Substances 0.000 title claims abstract description 13
- 229960002198 irbesartan Drugs 0.000 title claims abstract description 13
- 206010020772 Hypertension Diseases 0.000 title abstract description 8
- 150000001875 compounds Chemical class 0.000 title abstract description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 12
- 229920002261 Corn starch Polymers 0.000 claims abstract description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000008120 corn starch Substances 0.000 claims abstract description 6
- 239000008101 lactose Substances 0.000 claims abstract description 6
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 6
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 6
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 6
- 235000012239 silicon dioxide Nutrition 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 13
- 239000002671 adjuvant Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 238000011282 treatment Methods 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 5
- 238000004132 cross linking Methods 0.000 claims description 5
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 5
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 239000005555 hypertensive agent Substances 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 229940082195 hydrochlorothiazide 12.5 mg Drugs 0.000 claims description 3
- 229940080483 irbesartan 75 mg Drugs 0.000 claims description 3
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 3
- JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 abstract description 2
- 229960002003 hydrochlorothiazide Drugs 0.000 abstract description 2
- 230000000694 effects Effects 0.000 abstract 2
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
- 229940099112 cornstarch Drugs 0.000 abstract 1
- 229960001681 croscarmellose sodium Drugs 0.000 abstract 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 229960001375 lactose Drugs 0.000 abstract 1
- 229940057948 magnesium stearate Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 229960001866 silicon dioxide Drugs 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 201000010099 disease Diseases 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- -1 correctives) Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02146334 CN1199641C (zh) | 2002-10-24 | 2002-10-24 | 一种用于治疗高血压的复方厄贝沙坦胶囊 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 02146334 CN1199641C (zh) | 2002-10-24 | 2002-10-24 | 一种用于治疗高血压的复方厄贝沙坦胶囊 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1415298A CN1415298A (zh) | 2003-05-07 |
CN1199641C true CN1199641C (zh) | 2005-05-04 |
Family
ID=4751051
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 02146334 Expired - Lifetime CN1199641C (zh) | 2002-10-24 | 2002-10-24 | 一种用于治疗高血压的复方厄贝沙坦胶囊 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1199641C (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100417384C (zh) * | 2005-12-28 | 2008-09-10 | 严洁 | 厄贝沙坦氢氯噻嗪分散片 |
CN101780089B (zh) * | 2010-02-23 | 2011-08-17 | 北京四环科宝制药有限公司 | 厄贝沙坦氢氯噻嗪胶囊及其制备方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TR200301553A1 (tr) * | 2003-09-18 | 2005-10-21 | Nobel �La� Sanay�� Ve T�Caret A.�. | İrbesartan etken maddesi içeren yeni oral farmasötik formülasyonlar |
CN1732953B (zh) * | 2005-09-02 | 2010-05-05 | 姚俊华 | 一种治疗高血压的分散片 |
CN101199847B (zh) * | 2006-11-11 | 2011-10-12 | 深圳奥萨医药有限公司 | At1受体拮抗剂/利尿剂/叶酸联用的药物组合物及其用途 |
CN102335177B (zh) * | 2011-07-14 | 2013-05-01 | 海南锦瑞制药股份有限公司 | 一种口服固体药用组合物及其制备方法 |
CN102335178B (zh) * | 2011-07-14 | 2012-12-26 | 海南锦瑞制药股份有限公司 | 一种口服固体药用组合物及其制备方法 |
CN104352632B (zh) * | 2014-11-12 | 2017-11-24 | 扬子江药业集团北京海燕药业有限公司 | 一种柏艾胶囊作为肝转运体抑制剂的应用 |
-
2002
- 2002-10-24 CN CN 02146334 patent/CN1199641C/zh not_active Expired - Lifetime
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100417384C (zh) * | 2005-12-28 | 2008-09-10 | 严洁 | 厄贝沙坦氢氯噻嗪分散片 |
CN101780089B (zh) * | 2010-02-23 | 2011-08-17 | 北京四环科宝制药有限公司 | 厄贝沙坦氢氯噻嗪胶囊及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1415298A (zh) | 2003-05-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1267106C (zh) | 活化二甲硅油/无水磷酸钙组合物 | |
CN1199641C (zh) | 一种用于治疗高血压的复方厄贝沙坦胶囊 | |
CN1638715A (zh) | 制粒方法 | |
CA2448456A1 (en) | Solid pharmaceutical formulations comprising modafinil | |
CN1827112A (zh) | 一种治疗心血管疾病的分散片及其制备方法 | |
CN1260715A (zh) | 用罗西格列酮和胰岛素治疗糖尿病 | |
CN1742741A (zh) | 含氨基葡萄糖和钙剂及维生素d的药物组合物及其应用 | |
CN1568991A (zh) | 一种地氯雷他定分散片及其制备方法 | |
CN1682718A (zh) | 替米沙坦分散片及其制备方法 | |
CN1316978C (zh) | 复方硫酸氨基葡萄糖分散片制剂及其制备方法 | |
CN1269480C (zh) | 氯雷他定口腔崩解片及其制备方法 | |
CN1168451C (zh) | 噻唑烷二酮和磺酰脲组合物在制备治疗糖尿病的药物中的用途 | |
CN1178111A (zh) | 胃疾散 | |
CN1177603C (zh) | 银杏叶缓释片 | |
CN1827114A (zh) | 一种以盐酸依福地平为活性成分的药用组合物及其制备方法、用途 | |
CN1589793A (zh) | 鞣酸小檗碱在制备治疗溃疡性结肠炎药物中的应用 | |
CN1748771A (zh) | 一种治疗糖尿病的中药药物组合物及其制备方法和应用 | |
CN1188143C (zh) | 一种治疗感冒的药物 | |
CN1927166A (zh) | 特拉唑嗪缓释制剂 | |
CN1068519C (zh) | 一种治疗上消化道溃疡并有效抑制其复发的药物组合物 | |
CN1891286A (zh) | 一种安宫牛黄含片及其制备方法 | |
CN1965933A (zh) | 降压药茶及其制备方法 | |
CN1186017C (zh) | 防治糖尿病、高脂血症和肥胖症的药物的配制方法 | |
CN1557309A (zh) | 氨氯地平分散片及其制备方法 | |
CN1839882A (zh) | 一种治疗脚癣和体癣的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING BOKANGJIAN GENE TECHNOLOGY CO.,LTD. Free format text: FORMER OWNER: WANG DENGZHI Effective date: 20080125 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080125 Address after: No. 7, Spark Street, Changping science and Technology Park, Beijing Patentee after: Beijing Bokangjian Gene Technology Co.,Ltd. Address before: No. 7, Spark Street, Changping District science and Technology Park, Beijing Patentee before: Wang Dengzhi |
|
DD01 | Delivery of document by public notice |
Addressee: Li Hongguang Document name: Notification to Pay the Fees |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20050504 |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Li Hongguang Document name: Notice of Expiration and Termination of Patent Right |